-

05:29:51 PM

TLTFF Stock News

TLTFF - Theralase Technologies, Inc.

06/24/22 7:00 AM

OTC : TLTFF

Theralase® Research - One of the Top 10 Most Downloaded Papers

Theralase® Technologies Inc. (“ Theralase ” or the “ Company ”) ( TSXV: TLT) ( OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“ PDC ”) and their associated drug

RHEA-AI

positive

06/21/22 7:00 AM

OTC : TLTFF

clinical trial

Theralase® Phase Ib NMIBC Clinical Study Published

Theralase ® Technologies Inc. (“ Theralase ” or the “ Company ”) ( TSXV: TLT) ( OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“ PDC ”) and their associated

RHEA-AI

neutral

05/30/22 5:53 PM

OTC : TLTFF

Theralase Releases Q122 Interim Financial Statements

Theralase ® Technologies Inc. (“ Theralase ” or the “ Company ”) ( TSXV: TLT) ( OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated PhotoDynamic Compounds (“ PDC ”) and their associated drug

RHEA-AI

neutral

04/29/22 9:11 PM

OTC : TLTFF

Theralase Release FY2021 Audited Financial Statements

Theralase ® Technologies Inc. (“ Theralase ” or the “ Company ”) ( TSXV: TLT) ( OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated PhotoDynamic Compounds (“ PDC ”) and their associated

RHEA-AI

neutral

04/05/22 7:00 AM

OTC : TLTFF

clinical trial

Theralase® Provides Update on Phase II Bladder Cancer Clinical Study

Theralase ® Technologies Inc. (“ Theralase ” or the “ Company ”) ( TSXV: TLT) ( OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“ PDC ”) 1 and their associated

RHEA-AI

neutral

02/07/22 7:00 AM

OTC : TLTFF

covid-19

Theralase® Demonstrates Proof-of-Concept for Canadian-Made COVID-19 Vaccine

Theralase® Technologies Inc. (“ Theralase® ” or the “ Company ”) ( TSXV: TLT) ( OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds 1 (“ PDC ”) and their associated

RHEA-AI

neutral

12/09/21 7:00 AM

OTC : TLTFF

Theralase Expands Intellectual Property Portfolio

Theralase ® Technologies Inc. (“ Theralase ® ” or the “ Company ”) ( TSXV: TLT) ( OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“ PDCs ”) and their associated

RHEA-AI

neutral

11/29/21 6:00 PM

OTC : TLTFF

Theralase Releases 3Q21 Financial Statements and Newsletter

Theralase ® Technologies Inc. (“ Theralase ® ” or the “ Company ”) ( TSXV: TLT) ( OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated compounds and their associated drug formulations with a

RHEA-AI

neutral

08/30/21 6:15 PM

OTC : TLTFF

Theralase Releases Q221 Unaudited Financial Statements and Quarterly Newsletter

Theralase® Technologies Inc. (“ Theralase ” or the “ Company ”) ( TSXV: TLT) ( OTCQB: TLTFF), A clinical stage pharmaceutical company dedicated to the research and development of light activated compounds and their associated drug formulations with a

RHEA-AI

neutral

08/19/21 4:49 PM

OTC : TLTFF

management

Theralase Announces Leadership Transition

Theralase ® Technologies Inc. (“ Theralase ® ” or the “ Company ”) ( TSXV: TLT) ( OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“ PDC ”) and associated drug

RHEA-AI

positive

TLTFF Data

IndustryMedical Specialties
Websitehttp://www.theralase.com
CeoShawn Shirazi
Security nameTheralase Technologies Inc.
Issue typecs
SectorHealth Technology
Sic code3841
Tags
- Medical Specialties
- Health Technology
Address41 Hollinger Road
StateON
CityToronto
ZipM4B
CountryCA
Phone1.416.699.5273

About Theralase Technologies, Inc.

Theralase Technologies, Inc. engages in the design, development, and manufacture of patented laser technology platforms used in bio-stimulative and bio-destructive clinical applications in patients. It operates through the Medical Laser Technology (MLT), and Anti-Cancer Technology (ACT) segments. The MLT segment focuses on the company's medical laser business, which researches, develops, commercializes and manufactures lasers used by the ACT division. The ACT segment research and development of photo dynamic compounds (PDCs) for the treatment of cancer. The company was founded by Roger J. Dumoulin-White on August 22, 1989 and is headquartered in Toronto, Canada.